bbT-4015

N/A

Report date: 2025/01/26 15:01:19

Base Information

Drug NamebbT-4015

Drug Alias Nameanti-MUC16 CAR T-cell therapy (2seventy bio/Regeneron)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionMucin-16 modulators

TargetsMucin-16

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator Companies2seventy Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive Companies2seventy Bio Inc

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A